🟢 Icecure Medical is trading 5.71% up in after-hours trading; no clear catalyst identified

Icecure Medical is trading at $1.11, up 5.71%, with no clear after-hours catalyst identified.

• On October 20, Icecure Medical announced the first two patients enrolled at U.S. sites in its FDA-approved ChoICE breast cancer study.
• The update was published at 7:55 a.m. ET and describes study progress, but does not link it to the after-hours move.
• No clear after-hours trading-volume information was identified, and the available evidence does not establish that the study update or broader market sentiment caused the increase.